• Latest Posts

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

German Biotech Unveils Positive Phase II Results for Alzheimer’s

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers


TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

AC Immune receives Milestone Payment for Alzheimer Antibody